BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesCompany update

Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA ® (valbenazine) capsules across the KINECT ® clinical program Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™) SAN

Open original release

Related news

NBIXNeurocrine Biosciences2026-05-18 20:05 EST

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-05-06 12:30 EST

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

TEVATeva Pharmaceutical Industries2026-05-18 12:00 EST

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

TEVATeva Pharmaceutical Industries2026-06-08 12:00 EST

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

TNXPTonix Pharmaceuticals2026-07-15 13:05 EST

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

TNXPTonix Pharmaceuticals2026-05-27 11:00 EST

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

GHRSGH Research2026-03-25 15:11 EST

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

HRMYHarmony Biosciences2026-04-16 12:05 EST

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

View all latest news

Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, neurology, and endocrinology. Its commercial and development work centers on disorders with clear unmet need and durable treatment demand.

Recent company news

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

NBIXNeurocrine Biosciences2026-05-18 20:05 EST

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

NBIXNeurocrine Biosciences2026-05-06 12:30 EST

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Stock data

Close
176.41 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States